Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.
Type:
Grant
Filed:
June 20, 2016
Date of Patent:
December 10, 2019
Assignees:
V18 VZW, UNIVERSITEIT GENT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGE
Inventors:
Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman